BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for POINT Biopharma Global Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-12-20 4:38 pm Sale | 2023-12-18 | 13D | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -17,437,375 (Position Closed) | Filing |
| 2023-11-06 1:47 pm Purchase | 2023-11-02 | 13D | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND L P | 17,437,375 16.500% | 8,259,627 (+90.00%) | Filing |
| 2023-02-14 12:00 pm Purchase | 2022-12-31 | 13G | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND L P | 9,177,748 8.700% | 3,587,700 (+64.18%) | Filing |
| 2022-09-26 4:54 pm Purchase | 2022-09-14 | 13G | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND L P | 5,590,048 5.400% | 2,669,522 (+91.41%) | Filing |
| 2022-02-11 8:51 pm Purchase | 2021-12-31 | 13G | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND L P | 2,920,526 3.200% | 2,920,526 (New Position) | Filing |